Company intelligence / Profile preview

Xap Therapeutics

Cambridge, England, United Kingdom

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Xap Therapeutics is developing a synthetic biology-based, programmable cell therapy platform capable of delivering diverse therapeutic payloads with high specificity. The company is in the preclinical stage and has filed at least one patent related to methods and compositions for its technology. No clinical results have been reported as of June 2025.

Therapeutic areas: ImmunologyOncology
Modalities: Cell therapyCytokine (as payload)Antibody (as payload)Nucleic acid (as payload)Synthetic biology-driven cell therapeutics
Industry: Biotech

Beyond the preview

Go deeper on Xap Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xap Therapeutics.

Explore the full profile